Increased expression of NFATc1 in giant cell lesions of the jaws, cherubism and brown tumor of hyperparathyroidism

Pires Duarte,Alessandra; Cavaliéri Gomes,Carolina; Santiago Gomez,Ricardo; Rezende Amaral,Fabrício

doi:10.3892/ol.2011.274

Increased expression of NFATc1 in giant cell lesions of the jaws, cherubism and brown tumor of hyperparathyroidism

Authors:
- Alessandra Pires Duarte
- Carolina Cavaliéri Gomes
- Ricardo Santiago Gomez
- Fabrício Rezende Amaral
View Affiliations

Affiliations: Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte‑MG, CEP 31270 901, Brazil, Department of Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte‑MG, CEP 31270 901, Brazil
Published online on: March 21, 2011 https://doi.org/10.3892/ol.2011.274
Pages: 571-573

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A variety of diseases of the jaws may present multinucleated giant cells. These diseases include central giant cell lesions (CGCL), peripheral giant cell lesions (PGCL), brown tumor of hyperparathyroidism (BTH), and cherubism. The multinucleated giant cells in these lesions are osteoclast-like. Since NFATc1 plays a significant role in osteoclast differentiation, the present study aimed to compare the expression of NFATc1 in CGCL, PGCL, BTH and cherubism. A total of 14 formalin-fixed and paraffin-embedded tissue samples of CGCL (n=4), PGCL (n=5), BTH (n=3) and cherubism (n=2) were included in the study. An immunohistochemical analysis was performed to investigate the NFATc1 protein. The majority of giant cells in all of the cases were positive for nuclear NFATc1 and the immunostaining pattern was similar in all of the groups. Although our study supports the hypothesis that giant cell accumulation in PGCL, CGCL, BTH and cherubism is mediated by NFATc1, functional studies are required to investigate this hypothesis.

View Figures

View References

1	Katsikeris N, Kakarantza-Angelopoulou E and Angelopoulos AP: Peripheral giant cell granuloma. Clinicopathologic study of 224 new cases and review of 956 reported cases. Int J Oral Maxillofac Surg. 17:94–99. 1998. View Article : Google Scholar : PubMed/NCBI
2	De Lange J, van den Akker HP and van den Berg H: Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 104:603–615. 2007.PubMed/NCBI
3	Von Wowern N: Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 90:765–772. 2000.PubMed/NCBI
4	Hyckel P, Berndt A, Schleier P, Clement JH, Beensen V, Peters H and Kosmehl: Cherubism - new hypotheses on pathogenesis and therapeutic consequences. J Craniomaxillofac Surg. 33:61–68. 2005. View Article : Google Scholar : PubMed/NCBI
5	Pecovnik Balon B and Kavalar R: Brown tumor in association with secondary hyperparathyroidism. A case report and review of the literature. Am J Nephrol. 18:460–463. 1998.PubMed/NCBI
6	Bell SM, Shaw M, Jou YS, Myers RM and Knowles MA: Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. Genomics. 44:163–170. 1997. View Article : Google Scholar : PubMed/NCBI
7	Ueki Y, Tiziani V, Santanna C, et al: Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 28:125–126. 2001. View Article : Google Scholar : PubMed/NCBI
8	De Lange J, van Maarle MC, van den Akker HP and Redeker EJ: A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 103:378–381. 2007.PubMed/NCBI
9	Carvalho VM, Perdigao PF, Amaral FR, De Souza PE, De Marco L and Gomez RS: Novel mutations in the SH3BP2 gene associated with sporadic central giant cell lesions and cherubism. Oral Dis. 15:106–110. 2009. View Article : Google Scholar : PubMed/NCBI
10	Asagiri M and Takayanagi H: The molecular understanding of osteoclast differentiation. Bone. 40:251–264. 2007. View Article : Google Scholar : PubMed/NCBI
11	Lietman SA, Yin L and Levine MA: SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun. 371:644–648. 2008. View Article : Google Scholar : PubMed/NCBI
12	Novack DV and Faccio R: Jawing about TNF: new hope for cherubism. Cell. 128:15–17. 2007. View Article : Google Scholar : PubMed/NCBI
13	Amaral FR, Brito JA, Perdigao PF, et al: NFATc1 and TNF alpha expression in giant cell lesions of the jaws. J Oral Pathol Med. 39:269–274. 2010. View Article : Google Scholar : PubMed/NCBI
14	Itonaga I, Hussein I, Kudo O, Sabokbar A, Watt-Smith S, Ferguson D and Athanasou NA: Cellular mechanisms of osteoclast formation and lacunar resorption in giant cell granuloma of the jaw. J Oral Pathol Med. 32:224–231. 2003. View Article : Google Scholar : PubMed/NCBI
15	Adachi S, Amasaki Y, Miyatake S, Arai N and Iwata M: Successive expression and activation of NFAT family members during thymocyte differentiation. J Biol Chem. 275:14708–14716. 2000. View Article : Google Scholar : PubMed/NCBI
16	Wisniewska M, Stanczyk M, Grzelakowska-Sztabert B and Kaminska B: Nuclear factor of activated T cells (NFAT) is a possible target for dexamethasone in thymocyte apoptosis. Cell Biol Int. 21:127–132. 1997. View Article : Google Scholar : PubMed/NCBI
17	Wisniewska M, Pyrzynska B and Kaminska B: Impaired AP-1 dimers and NFAT complex formation in immature thymocytes during in vivo glucocorticoid-induced apoptosis. Cell Biol Int. 28:773–780. 2004. View Article : Google Scholar : PubMed/NCBI
18	Abdo EN, Alves LC, Rodrigues AS, Mesquita RA and Gomez RS: Treatment of a central giant cell granuloma with intralesional corticosteroid. Br J Oral Maxillofac Surg. 43:74–76. 2005. View Article : Google Scholar : PubMed/NCBI
19	Carlos R and Sedano HO: Intralesional corticosteroids as an alternative treatment for central giant cell granuloma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 93:161–166. 2002. View Article : Google Scholar : PubMed/NCBI
20	Adornato MC and Paticoff KA: Intralesional corticosteroid injection for treatment of central giant-cell granuloma. J Am Dent Assoc. 132:186–190. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kim HJ, Zhao H, Kitaura H, et al: Glucocorticoids and the osteoclast. Ann N Y Acad Sci. 1116:335–339. 2007. View Article : Google Scholar